The trajectory of Sildenafil presents a complex picture for shareholders. While the initial introduction generated substantial returns, the lapse of its patent opened the door to generic versions, dramatically https://bookmark-share.com/story21710172/the-copyright-and-big-pharma-a-risky-bet